Race track

Hitting the Accelerator

The Therapeutic Goods Administration’s (TGA) priority pathway provides a formal mechanism for faster assessment of vital and life-saving prescription medicines. The priority review pathway is suitable for products with a...

Prescription Medicine Pathways

The standard regulatory evaluation pathway in Australia for new prescription medicines involves a thorough TGA review of data demonstrating safety, efficacy +/- quality. In addition to the standard regulatory pathway...
Vaccine and Vial

Provisionally yours

The development of new medicines and expanding the use of existing medicines is a resource-intensive process, where it can take a number of years to complete the clinical trials necessary...

Formulated ingredients and premixes: Keeping the IP of a PI

Formulated ingredients or premixes are commonly used in many medicinal products – such as inks, coatings and colourants, fragrances and flavours, dosage form bases, and triturations or extracts of active...

Your guide to claiming temporary exemption from TGO91/92 compliance

As described in the article, Addendum to TGA Deadlines: Medicine Labelling Compliance and COVID-19, 31 August 2020 marked the end of the medicines packaging reform transition. The intent of the...

Australian Prescription Medicine Pathways – Project Orbis

Project Orbis is an initiative of the US FDA Oncology Centre of Excellence (OCE). The intent of Project Orbis is to provide a framework for concurrent submission and review of...
shutterstock_181476422 (1)

Addendum to TGA Deadlines: Medicine Labelling Compliance and COVID-19

As described in the Upcoming TGA Deadlines for Medicine Labelling and Product Information Reform article the transition period for Australian Medicines Packaging Reform concludes on 31 August 2020. As a...
Medicine packaging

Upcoming TGA Deadlines for Medicine Labelling and Product Information Reform

2020 was flagged to be a big year for TGA Sponsors of Medicines with two long-standing milestones on the horizon. Whilst there is no doubt this won’t be a year...
Time passing

TGA expedites COVID-19 approvals, while keeping up business as usual for other devices

The TGA continues to provide timely responses and support for new applications and emergency use applications. Our firm continues to be in active communication with the agency, which at the...
Grant Feb artgicle image

Australian regulator closes in on Class I devices

In 2014, the Australian Government announced the Expert Panel Review of Medicines and Medical Devices Regulation, which was tasked to assess and provide feedback on the regulatory framework for medicines...


Recent Posts